Technological advances in the monitoring of glucose and dosing of insulin for diabetes patients has led JP Morgan analyst Kevin Sayer to upgrade shares of Dexcom to "overweight" and raise his price target on the firm from $ 80 to $ 80 . We offer performance and accuracy that others don't." San Diego firm Dexcom makes continuous glucose monitoring devices ( CGM ) that attach to a patient's skin, and treatment is moving in the direction of integrated pumps that link insulin dosage to CGMs, Marcus said. Dexcom 's system also provides tools that connect to phones and share data with treatment providers, CEO Kevin Sayer explained. Dexcom 's share price has risen 62% Friday .
Technological advances in the monitoring of glucose and dosing of insulin for diabetes patients has led JP Morgan analyst Kevin Sayer to upgrade shares of Dexcom to "overweight" and raise his price target on the firm from $ 80 to $ 80 . San Diego firm Dexcom makes continuous glucose monitoring devices ( CGM ) that attach to a patient's skin, and treatment is moving in the direction of integrated pumps that link insulin dosage to CGMs, Marcus said. Dexcom 's system also provides tools that connect to phones and share data with treatment providers, CEO Kevin Sayer explained. Dexcom 's share price has risen 62% Friday .